BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. Due to very poor 5-year-survival new therapeutic …

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. In light of the very poor 5-year-survival new therapeutic …

AIM: To examine the underlying mechanisms of erlotinib-induced growth inhibition in
hepatocellular carcinoma (HCC). METHODS: Erlotinib-induced alterations in gene …

AIM: To investigate the inhibitory effect of gefitinib combined with cytotoxic agent cisplatin
(CDDP) on hepatocellular carcinoma (HCC). METHODS: Female Kunming mice and H22 …

4143 Background: Worldwide, hepatocellular carcinoma (HCC) is the most common cause
of cancer death. Chemotherapy yields no survival benefit, and median survival is< 6 months …

Epidermal growth factor receptor (EGFR) binds transforming growth factor α (TGF‐α) which
is mitogenic for hepatocytes. Diverse lines of evidence suggest that activation of the TGF …

Hepatocellular carcinoma (HCC) is a highly malignant cancer with poor prognosis. Inhibitors
of EGFR and VEGFR for HCC treatment are currently under investigation. Gefitinib and …

Epidermal growth factor receptor (EGFR)‐and type 1 insulin‐like growth factor receptor (IGF‐
1R)‐dependent pathways are up‐regulated in hepatocellular carcinoma (HCC), and cross …

Epidermal growth factor receptor (EGFR) is overexpressed in a significant proportion of
hepatocellular carcinomas. Recent studies of EGFR inhibitors to treat hepatocellular …

BACKGROUND & AIMS: Transforming growth factor-beta (TGF-β) induces apoptosis in
hepatocytes, a process that is inhibited by the epidermal growth factor receptor (EGFR) …